Erich Froese

Erich Froese supports clients with research and analysis that spans a variety of healthcare sectors and stakeholders.

He applies his background in clinical research and disease surveillance to a broad range of client projects.

Prior to joining Avalere, Erich was a research assistant on a traumatic brain injury study at Walter Reed National Military Medical Center where he managed clinical visits and conducted participant interviews. Additionally, he held an internship position with the San Antonio Metropolitan Health Department where he helped develop a citywide health promotion campaign and created a comprehensive health assessment to explore chronic disease outcomes in the area. Erich has also held internship positions with the US Air Force and the Center for Behavioral Health & Technology.

Erich has a BA in psychology and public health from the University of Virginia.

Authored Content

The TDAPA supports payment and patient access to new therapies introduced to the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS). While no major TDAPA revisions were finalized in the Calendar Year (CY) 2021 ESRD PPS Final Rule, stakeholders should continue to monitor this payment adjustment policy, as it has evolved since its introduction and may continue to change in future rulemaking cycles.

The ESRD Treatment Choice model demonstrates an increased focus on improving health outcomes for Medicare patients receiving dialysis by realigning incentives to favor the adoption of home dialysis and increasing the rate at which patients receive kidney transplants. This mandatory model could lead to significant disruption for stakeholders in the coming years. Understanding the risk and opportunities associated with this model will be critical for patients, providers, and manufacturers alike.